

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 16262

Title: Incretin manipulation in diabetes management

Reviewer's code: 00340582

Reviewer's country: Japan

Science editor: Yue-Li Tian

Date sent for review: 2015-01-08 20:14

Date reviewed: 2015-03-01 11:27

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The editorial regarding to incretins therapy for type 2 diabetes is well-organized and written.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 16262

Title: Incretin manipulation in diabetes management

Reviewer's code: 00506409

Reviewer's country: United States

Science editor: Yue-Li Tian

Date sent for review: 2015-01-08 20:14

Date reviewed: 2015-02-25 00:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

In this manuscript the authors review medicines targeting incretin as a means to affect type 2 diabetes. The rationale for targeting incretin is well presented in the description of pathophysiological pathways illustrated by an informative figure. Two major classes of drugs are introduced, namely analogues of glucagon-like peptide-1, and inhibitors of dipeptidyl peptidase-4. For individual drugs pharmacokinetic parameters are given, and an overview of efficacy and adverse side effects. Since there were concerns about safety of the drugs, the authors give special attention to adverse effects data, which are summarized in tabular format. They conclude that presently available incretin-based medicines are quite promising in the management of type 2 diabetes, and that possible adverse effects like pancreatitis and cancer need to be further addressed. This is a well written short review (or well-sized editorial). The manuscript brings concise information, and the presentation is clear. There are only a few suggestions: ? Section on GLP-1 analogues: data on Hb1Ac reduction, body weight etc, for the individual drugs can be compiled in a table, this table can be separate from the present Table 1. ? Section on DPP-4 inhibitors: can you give more details on data about clinical efficacy, similar to such data provided for GLP-1 analogues? Also



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

here, a Table would be helpful, which can be separate from the present Table 2.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

ESPS manuscript NO: 16262

Title: Incretin manipulation in diabetes management

Reviewer's code: 00674619

Reviewer's country: Romania

Science editor: Yue-Li Tian

Date sent for review: 2015-01-08 20:14

Date reviewed: 2015-02-27 22:27

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The incretin concept is very interesting and important for type 2 diabetes management. There has been a lot of interest in developing incretin-based therapies for the treatment of type 2 diabetes. For this reason, this subject on the theory of incretins and their handling in type 2 diabetes is of great interest. The manuscript is very well organized and the data are well and clear presented. Moreover, the present topic appears timely. My opinion is that, this paper is very good regarding the drug options for the patients with type 2 diabetes. The manuscript is state-of-the-art and the presented results are of potential interest for a wide readership, therefore I recommend publication in 'World Journal of Diabetes'.